Results for tag: "Canagliflozin"

Canagliflozin is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to lower blood sugar levels. Canagliflozin is typically used in combination with other diabetes medications, such as metformin, to help control blood sugar levels. Canagliflozin is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2013. It has become increasingly popular in recent years, as it is an effective treatment for type 2 diabetes and has fewer side effects than other diabetes medications. The Canagliflozin market is an important part of the Endocrine and Metabolic Disorders Drugs market. It is a growing market, with more and more people being diagnosed with type 2 diabetes each year. As such, the demand for Canagliflozin and other SGLT2 inhibitors is expected to continue to rise. Some companies in the Canagliflozin market include Johnson & Johnson, Merck, and AstraZeneca. Show Less Read more